BioSpace News Archive

Mersana Therapeutics, Inc. announced that on August 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25,575 shares of its common stock and restricted stock unit awards to acquire an aggregate of 32,475 shares of its common stock, to 8 new employees whose employment commenced in July 2022.

Rain Therapeutics Inc., a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, reported financial results for the second quarter and six months ended June 30, 2022, along with an update on the Company’s key developments, business operations and upcoming milestones.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its second quarter 2022 financial results on Thursday, August 11, 2022.

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, reported financial results for the three and six months ended June 30, 2022 and provided a business update.

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, provided a corporate update and reported financial results for the second quarter ended June 30, 2022.

Allakos Inc., a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, provided a business update and reported financial results for the second quarter ended June 30, 2022.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced second quarter 2022 financial results and provided an operational update.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, reported second quarter 2022 financial results and recent operational progress.

Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, reported second quarter financial results for the period ending June 30, 2022 and provided business updates.

Maravai LifeSciences Holdings, Inc., a global provider of life science reagents and services to researchers and biotech innovators, reported financial results for the second quarter ended June 30, 2022, together with other business updates.